Volume 138, Issue 1, Pages 108-115 (January 2010) Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C Maria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Roberta Soffredini, Ersilio Del Ninno, Antonio Russo, Massimo Colombo Gastroenterology Volume 138, Issue 1, Pages 108-115 (January 2010) DOI: 10.1053/j.gastro.2009.08.071 Copyright © 2010 AGA Institute Terms and Conditions
Figure 1 Flow chart of the MIST study. aNineteen patients met the week 12 stopping rule, 7 patients met the week 24 stopping rule, and 2 patients had a virologic breakthrough. Twenty of 28 patients were HCV-1, and 8 were HCV-4. bThirty-two patients met the week 12 stopping rule; 15 patients met the week 4 stopping rule; and 3 patients had a virologic breakthrough. Thirty-five of 50 patients were HCV-1, and 15 were HCV-4. Gastroenterology 2010 138, 108-115DOI: (10.1053/j.gastro.2009.08.071) Copyright © 2010 AGA Institute Terms and Conditions
Figure 2 Rates of virologic response for the patients with chronic hepatitis C receiving RBV combined with PegIFN-α2a or PegIFN-α2b. RVR, rapid; cEVR, complete early; EOT, end of treatment; and SVR, sustained virologic. Gastroenterology 2010 138, 108-115DOI: (10.1053/j.gastro.2009.08.071) Copyright © 2010 AGA Institute Terms and Conditions